Aprea Therapeutics, Inc.
APRE
$1.40
-$0.05-3.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -27.32% | -21.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -27.32% | -21.04% | |||
| Cost of Revenue | -22.99% | 5.26% | |||
| Gross Profit | 22.69% | -7.77% | |||
| SG&A Expenses | -9.71% | 64.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.47% | 23.78% | |||
| Operating Income | 17.08% | -26.65% | |||
| Income Before Tax | 17.64% | -35.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.64% | -35.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.64% | -35.85% | |||
| EBIT | 17.08% | -26.65% | |||
| EBITDA | 17.10% | -26.69% | |||
| EPS Basic | 18.85% | -34.97% | |||
| Normalized Basic EPS | 18.85% | -34.99% | |||
| EPS Diluted | 18.85% | -34.97% | |||
| Normalized Diluted EPS | 18.85% | -34.99% | |||
| Average Basic Shares Outstanding | 1.49% | 0.66% | |||
| Average Diluted Shares Outstanding | 1.49% | 0.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||